Final Glance: Biotechnology companies
AP - Tue May 06, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Tue May 06, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue May 06, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Celgene Announces Offering of Senior Unsecured Notes
Business Wire - Tue May 06, 7:31AM CDT
Celgene Corporation (NASDAQ:CELG) today announced its intention to offer, subject to market and other conditions, senior unsecured notes under a shelf registration statement on Form S-3 on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.
Is Merrimack Pharmaceuticals Worth More Than $700 Million?
Todd Campbell, The Motley Fool - Motley Fool - Mon May 05, 8:30AM CDT
When patients are diagnosed with diseases like pancreatic cancer where survival is measured in months, not years, any advance is an important one. That's why oncologists and patients are watching Merrimack Pharmaceuticals . Merrimack just...
Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene
PR Newswire - Mon May 05, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), WellPoint Inc. (NYSE: WLP), UnitedHealth Group Inc. (NYSE: UNH), Forest Laboratories Inc. (NYSE: FRX) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2020-100free.
1 Biotech's Earnings the Market Got Completely Wrong
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun May 04, 2:03PM CDT
In this segment from Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass look at the recent earnings report from biotech company Celgene , to sift out the vital numbers that investors need to know. The guys...
Biotech Sector Performance in April: Gilead Sciences Rising
at The Street - Fri May 02, 8:49AM CDT
The biotech sector was down again, but there's some hopeful signs of a recovery.
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
Up 50%: Merrimack Pharmaceuticals' Groundbreaking News
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Thu May 01, 5:30PM CDT
Shares in Merrimack Pharmaceuticals (NASDAQ: MACK) gained over 50% today on great news regarding a phase 3 trial for its MM-398 drug for pancreatic cancer. In combination with 5-flouroacil and leucovorin, MM-398 generated a 1.9 month lift in...